A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation

NCT06990711 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Antibody Mediated Rejection of Lung Transplant

Interventions

DRUG: Siltuximab
DRUG: Placebo

Sponsor

Washington University School of Medicine

Collaborators

[object Object]
[object Object]